Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of GB223 in Healthy Adults
NCT04178044Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GB223 in Giant Cell Tumor of Bone (GCTB), postmenopausal osteoporosis and bone metastasis (5 arms), sponsored by Genor Biopharma. Primary endpoints: Adverse Effect up to 252 days, Serious Adverse Effect up to 252 days and 9 more. Status: unknown.
02
Drugs
GB223
03
Conditions
Giant Cell Tumor of Bone (GCTB)postmenopausal osteoporosisbone metastasis
Beyond the preview
Go deeper on NCT04178044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178044.